Sales of Novo Nordisk's Victoza drop in US

Diabetes drug Victoza has had lower sales this year than during the same period last year.

Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk's best selling drug, diabetes medicine Victoza, has lost momentum in the US over the past few weeks.

Sales have fallen by 2 percent over the past month, data provided by US analysis house Symphony Health shows.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs